Le Lézard
Classified in: Health
Subjects: RCL, PSF, CFG

Public advisory - APO-Mometasone nasal spray: Two lots recalled due to possible risk of infection


OTTAWA, ON, Feb. 19, 2024 /CNW/ - 

Summary

APO-Mometasone nasal spray, 50 mcg/metered spray (CNW Group/Health Canada (HC))

Affected products

Product

DIN

Lot

Expiry

APO-Mometasone nasal spray, 50 mcg/metered spray

02403587

TX5343

TZ2586

Sep 2025

Oct 2025

 
Issue

Apotex Inc. is recalling two lots of APO-Mometasone nasal spray due to possible bacterial contamination with Burkholderia cepacia complex (Bcc). Bcc is a group of bacteria that poses a low  medical risk to most healthy people; however, children, those with chronic lung diseases, people who are pregnant, seniors and those with a weakened immune system may be at a higher risk of illness.

APO-Mometasone nasal spray is a prescription drug used to treat seasonal and year-round nasal allergy symptoms (such as itchy, stuffy or runny nose and sneezing) in children 3-11 years old. It is also used to treat sinusitis (sinus inflammation) in adults and children 12 years of age and older, and nasal polyps in adults.

The effects of Bcc vary widely, ranging from no symptoms at all to serious infections. In severe cases, Bcc can lead to bloodstream infections that may result in sepsis (a serious medical condition caused by an overwhelming immune response to an infection) and death. Bcc is often resistant to common antibiotics. People experiencing persistent or worsening symptoms, such as fevers, or facial pain or pressure, should seek medical attention.

Health Canada is monitoring the company's recall and its implementation of corrective and preventative actions. Supply might be temporarily constrained as a result of this recall. You should speak to your healthcare provider about what suitable alternative treatments are available to you or your child.

What you should do

Également disponible en français

SOURCE Health Canada (HC)


These press releases may also interest you

at 01:05
Today scientists from Colossal Biosciences, the world's first de-extinction company, and the University of Melbourne announce a major step forward in the effort to save Australia's endangered northern quoll (Dasyurus hallucatus) from the invasive...

at 01:00
Global Heart Hub, the international alliance of heart...

7 mai 2024
Kirin Holdings Company, Limited (Kirin Holdings)(TOKYO:2503) and National Institute of Infectious Diseases (NIID) are jointly conducting studies to investigate the protective efficacy of L. lactis strain Plasma [postbiotic] (LC-Plasma) immunization...

7 mai 2024
Since 2019, NSG BioLabs has been a leader in co-working lab spaces in Singapore, and has nurtured over 40 biotech companies, of which the startups have achieved nearly US$400 million funding in total alongside significant business milestonesNSG...

7 mai 2024
Today, The Kids Mental Health Foundation (KMHF) hosted a panel alongside the Mental Health Storytelling, which is housed at the USC Annenberg Inclusion Initiative, in New York City. The...

7 mai 2024
The Board of Juno Pharmaceuticals Corporation is excited to announce the appointment of Jean-Guy Goulet as Chief Executive Officer (CEO). An executive with over 35 years of experience in the pharmaceutical industry, overseeing activities in Canada...



News published on and distributed by: